Metastatic Prostate Cancer

SAN FRANCISCO  — The addition of niraparib to abiraterone acetate and prednisone improved outcomes for certain men with prostate cancer, according to randomized phase 3 study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO  — A novel risk-prediction tool based on 290 genetic variants correctly identified men with high or low lifetime risks for developing metastatic or fatal prostate cancer, according to a study presented at ASCO Genitourinary Cancers Symposium.

A substantial number of deaths among men with metastatic prostate cancer resulted from noncancer causes, including cardiovascular disease, according to a retrospective cohort study published in JAMA Network Open.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses two posters on prostate cancer therapies presented at the ESMO Congress 2021.

In this video, Alicia Morgans, MD, discusses the PEACE-1 phase 3 trial that found adding abiraterone to androgen deprivation therapy plus docetaxel improves radiographic PFS and OS in men with metastatic castration-sensitive prostate cancer.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses a phase I/II multicenter first-in-human trial of DS-7300, an anti-B7-H3, which was studied in patients with advanced solid tumors.

Nivolumab plus rucaparib demonstrated activity among men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of cohort A2 of the CheckMate 9KD trial presented during the virtual ESMO Congress 2021.

A randomized phase 3 study that assessed the addition of olaparib to abiraterone as first-line treatment for men with metastatic castration-resistant prostate cancer met its primary endpoint, according to the agent’s manufacturer.

Adding abiraterone acetate to androgen deprivation therapy plus docetaxel improved radiographic PFS and OS among men with metastatic castration-sensitive prostate cancer, according to data presented during the virtual ESMO Congress 2021.

The FDA granted breakthrough therapy designation to 177Lu-PSMA-617 for treatment of metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.